A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Prostate Cancer|Salivary Gland Cancer|Endometrial Cancer|Squamous Cell Carcinoma of the Cervix|Breast Cancer|Ovarian Cancer
Interventions: DRUG: OPB-111001
Sponsor: Otsuka Novel Products GmbH